GlassScriptPhysician profile
Ashley Marie Brundrett
NPI 1841630639
$4,053.69
in general payments reported to CMS, 2019-2025
23 companies · $923 in 2025
The $923 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $257 · 2021: $485 · 2022: $239 · 2023: $579 · 2024: $771 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.07 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,178.07 | 2019-2025 | Centurion, Clareon, Wavelight Refractive Suite |
| Allergan, INC. | $543.16 | 2019-2022 | |
| Sight Sciences, INC. | $297.90 | 2024-2025 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $295.46 | 2020-2025 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
| Shire North American Group INC | $275.48 | 2019 | |
| Bausch & Lomb Americas INC. | $203.91 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $188.79 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $143.38 | 2022-2024 | Cequa |
| Apellis Pharmaceuticals, INC. | $119.32 | 2023 | |
| Optovue, INC. | $100.00 | 2019 | |
| Optos, INC. | $98.66 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.83 | 2019-2021 | |
| Rxsight INC | $88.48 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Abbvie INC. | $75.28 | 2022-2023 | Durysta |
| Biotissue Holdings INC. | $63.63 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $62.79 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $54.52 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $40.34 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $36.68 | 2019 | |
| Carl Zeiss Meditec, INC. | $31.60 | 2019 | |
| Aerie Pharmaceuticals, INC. | $29.37 | 2019-2021 | |
| Coopervision INC. | $15.63 | 2024 | Synergeyes Contact Lens |
| Amgen INC. | $14.41 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Brundrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.